Skip to main content

Table 3 Univariate and multivariate analysis of relationships between baseline patient characteristics or early changes in biomarker concentrations and clinical outcome

From: Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

 

n*

TTP

OS

HR†

95% CI

p

HR†

95% CI

p

Univariate analysis

       

 Age (< 65 vs. ≥ 65 years)

59/5

1.19

0.43-3.33

0.74

3.09

1.17-8.16

0.023

 Race (white vs. non-white)

52/11

0.39

0.18-0.86

0.019

0.67

0.26-1.72

0.40

 ECOG performance status (0 vs. ≥ 1)

24/40

1.20

0.70-2.04

0.53

1.58

0.78-3.21

0.21

 ER (+ vs. −)

37/27

1.14

0.66-1.96

0.64

1.60

0.80-3.20

0.18

 PgR (+ vs. −)

26/35

0.88

0.50-1.54

0.65

1.60

0.81-3.16

0.17

 HER2 (+ vs. −)

12/48

0.74

0.38-1.45

0.38

0.70

0.29-1.69

0.43

 Triple-negative (yes vs. no)

20/43

0.99

0.56-1.76

0.97

0.67

0.31-1.42

0.29

 Baseline sKIT (continuous‡)

61

1.00

0.97-1.02

0.82

0.99

0.96-1.02

0.48

 Baseline VEGF-A (continuous‡)

63

1.11

0.98-1.27

0.11

1.10

0.95-1.28

0.22

 Baseline sVEGFR-2 (continuous‡)

62

0.99

0.89-1.10

0.83

0.91

0.80-1.03

0.15

 Baseline sVEGFR-3 (continuous‡)

54

1.00

0.99-1.01

0.77

1.00

0.99-1.01

0.97

 sKIT change (≥ 48.6% vs. < 48.6%)

30/31

4.36

2.38-7.97

< 0.0001

2.28

1.13-4.60

0.022

 VEGF-A change (≥ 89.4% vs. < 89.4%)

31/30

1.71

0.99-2.96

0.054

2.25

1.09-4.65

0.029

 sVEGFR-2 change (≥ 55.8% vs. < 55.8%)

31/30

1.14

0.67-1.94

0.63

1.37

0.68-2.74

0.37

 sVEGFR-3 change (≥ 52.8% vs. < 52.8%)

28/27

1.39

0.79-2.45

0.26

1.66

0.79-3.52

0.18

 sKIT change (continuous‡)

61

0.93

0.91-0.96

< 0.0001

0.94

0.92-0.97

< 0.0001

 VEGF-A change (continuous‡)

61

0.99

0.97-1.01

0.21

0.98

0.96-1.00

0.042

 sVEGFR-2 change (continuous‡)

61

1.00

0.98-1.02

0.95

0.99

0.97-1.01

0.45

 sVEGFR-3 change (continuous‡)

55

0.99

0.98-1.01

0.38

0.98

0.96-1.00

0.051

Multivariate analysis of factors showing significance in univariate analysis §

 Model using categorical variables

       

   Age (< 65 vs. ≥ 65 years)

−

−

−

−

4.45

1.59-12.48

0.0045

   Race (white vs. non-white)

−

0.30

0.12-0.70

0.0055

−

−

−

   sKIT change (≥ 48.6% vs. < 48.6%)

−

4.75

2.48-9.08

< 0.0001

2.69

1.29-5.64

0.0085

   VEGF-A change (≥ 89.4% vs. < 89.4%)

−

1.62

0.93-2.80

0.086

2.10

1.01-4.34

0.047

 Model using continuous variables

       

   Age (continuous‡)

−

−

−

−

1.05

1.00-1.09

0.047

   Race (white vs. non-white)

−

0.25

0.11-0.61

0.0021

−

−

−

   sKIT change (continuous‡)

−

0.92

0.90-0.95

< 0.0001

0.94

0.92-0.97

< 0.0001

  1. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HR, hazard ratio; OS, overall survival; PgR, progesterone receptor; sKIT, soluble KIT; sVEGFR, soluble vascular endothelial growth factor receptor; TTP, time to tumor progression; VEGF, vascular endothelial growth factor.
  2. *Number of patients analyzed in univariate analysis (for categorical variables, numbers for both groups are shown).
  3. †For categorical variables, HR > 1 favors the first category and HR < 1 favors the second category; for continuous variables, HR > 1 favors the value when it decreases and HR < 1 favors the value when it increases.
  4. ‡Modeled as a continuous variable.
  5. §n = 60 for the TTP models because race was unknown in one patient, and n = 61 for the OS models.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us